Travere Therapeutics (TVTX) Short term Debt (2013 - 2025)

Travere Therapeutics has reported Short term Debt for 13 years, with the latest figure at $68.8 million in Q2 2025.

• For the quarter ending Q2 2025, Short term Debt changed N/A year-over-year to $68.8 million; the trailing twelve-month figure through Jun 2025 stood at $68.8 million (changed N/A YoY), and the FY2024 full-year result was $68.7 million, changed N/A from the prior year.
• Short term Debt for Q2 2025 stood at $68.8 million, roughly flat from $68.8 million in the prior quarter.
• The five-year high for Short term Debt was $68.8 million in Q2 2025, with the low at $6.9 million in Q1 2023.
• Historically, Short term Debt has averaged $29.6 million across 5 years, with a median of $7.4 million in 2021.
• Annual changes were most pronounced in 2021 — Short term Debt slumped 57.47% — and 2022, when it dropped 5.41%.
• Travere Therapeutics' Short term Debt stood at $7.4 million in 2021, then retreated by 5.41% to $7.0 million in 2022, then retreated by 1.43% to $6.9 million in 2023, then surged by 895.33% to $68.7 million in 2024, then rose by 0.23% to $68.8 million in 2025.
• The last three Short term Debt figures came in at $68.8 million (Q2 2025), $68.8 million (Q1 2025), and $68.7 million (Q4 2024), per Business Quant data.